Based on previous preclinical data showing activity of Src inhibition in CRC cell lines, this study sought to investigate the efficacy of dasatinib, an ATP-site competitive, orally bioavailable inhibitor of Src family kinases, BCR-ABL, ephrin (EPH), c-Kit, and PDGFRβ, in the treatment of CRC cell lines and xenograft mouse models [19, 24]. This evidence concerns the gene SRC and colorectal carcinoma.